Published in Am Heart J on February 02, 2011
Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci (2011) 1.37
The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. Biochim Biophys Acta (2011) 1.03
Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. PLoS One (2013) 0.90
Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. J Lipid Res (2012) 0.87
HDL and cognition in neurodegenerative disorders. Neurobiol Dis (2014) 0.84
Triglyceride to high-density lipoprotein cholesterol ratio predicts cardiovascular outcomes in prevalent dialysis patients. Medicine (Baltimore) (2015) 0.83
Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications. Health Serv Res (2012) 0.83
Testing cardiovascular drug safety and efficacy in randomized trials. Circ Res (2014) 0.82
Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease. Kidney Res Clin Pract (2012) 0.81
Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men. Steroids (2012) 0.80
Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives? World J Diabetes (2015) 0.78
Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. Cardiovasc Diabetol (2015) 0.77
Sunlight exposure and cardiovascular risk factors in the REGARDS study: a cross-sectional split-sample analysis. BMC Neurol (2014) 0.77
Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney Int (2015) 0.76
Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL. Int J Mol Sci (2015) 0.75
Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia. Arch Med Sci (2014) 0.75
Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters. Clin Med Insights Cardiol (2011) 0.75
Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome. Wien Klin Wochenschr (2016) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 25.68
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med (1990) 6.43
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27
Antiinflammatory properties of HDL. Circ Res (2004) 5.41
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation (2000) 4.87
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. Am J Cardiol (2009) 2.16
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation (2009) 1.73
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 1.69
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin (2006) 1.53
LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes. Acta Diabetol (2002) 0.92
Very low density lipoprotein apolipoprotein B metabolism in humans. Klin Wochenschr (1988) 0.79